AI entity
All 1 tracked stories fall under one category: ai-models. Of the tracked stories, 1 of 1 also mention Eli Lilly, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.
Last mentioned: Mar 23, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: ai-models. Of the tracked stories, 1 of 1 also mention Eli Lilly, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. The 6 average consequence score is below the beat benchmark of 6.4 in the same window. tirzepatide appears in 1 tracked AI story from March 4, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 AI stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering tirzepatide. Shared-story counts are live from our verified record — not editorial picks.
As the AI sector matures in 2026, investors are pivoting toward companies that successfully integrate generative AI and machine learning into specialized verticals like healthcare and voice automation. Key players including Eli Lilly and SoundHound AI are demonstrating how AI-powered drug discovery and conversational interfaces are translating into significant revenue growth and market leadership.
tirzepatide is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
